EUVIMEDEUVIMED entdecken
Crossref

Ayurveda, Unani, Siddha, and Homoeopathy Medicines as an Adjuvant in the Treatment of COVID-19

Danish Javed, Ashish Kumar Dixit, Sukhes Mukherjee, Sana Anwar, Nibha Giri

Journal of Primary Care Specialties · 2022

DOI: 10.4103/jopcs.jopcs_13_22 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Primary Care Specialties, 2022. Verfasst von Danish Javed und 4 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: Ayurveda, Yoga, Unani, Siddha, and Homoeopathy (AYUSH); India's traditional medical system has made significant contributions to COVID-19. However, the results of controlled trials were mixed. To reach factual conclusions, we conducted systematic study and meta-analysis. Materials and Methods: An exhaustive literature search on COVID-19 and AYUSH was conducted using electroinic databases such as PubMed/Medline, CAM-QUEST, and the Cochrane Central Register of Controlled Trials since inception to February 2022. Pooled estimates of the parameters were assessed in terms of standard mean difference (SMD) and relative risk (rr) using RevMan software. Risk of bias (RoB) in individual studies and across studies was assessed through Cochrane tool of bias and Grades of Recommendation, Assessment, Development, and Evaluation approach, respectively.

Results

A total of 13 studies out of 650 articles were considered for the meta-analysis. Combined therapy showed greater effect to recovery rate and period (RR = 0.24, 95% confidence interval [CI] [0.11–0.55] P = 0.0007) (mean differences [MD] = −2.29, 95% CI − 4.62–0.04, P = 0.05), respectively. Cycle threshold value of reverse transcription polymerase chain reaction (MD = −2.16, 95% CI − 2.90– −1.43, P < 0.00001), interleukin (IL)-6 (MD = −0.31, 95% CI − 0.57 –−0.05, P = 0.02), tumor necrosis factor-alpha (MD = −3.38, 95% CI − 4.25 – −2.51, P < 0.00001), lactate dehydrogenase (MD = −1.97, 95% CI − 2.57 to − 1.38, P < 0.00001). In homeopathy preventive trial, lesser number of occurrences of events were found (odds ratio = 0.12, 95% CI 0.03–0.47, P = 0.002). RoB was unclear.

Conclusion

COVID-19 may benefit from AYUSH interventions as an adjunct. High-quality randomized controlled trials are required to evaluate and validate this.

Zitieren

APA

Javed, D., Dixit, A. K., Mukherjee, S., Anwar, S., & Giri, N. (2022). Ayurveda, Unani, Siddha, and Homoeopathy Medicines as an Adjuvant in the Treatment of COVID-19. Journal of Primary Care Specialties. https://doi.org/10.4103/jopcs.jopcs_13_22

Vancouver

Javed D, Dixit AK, Mukherjee S, Anwar S, Giri N. Ayurveda, Unani, Siddha, and Homoeopathy Medicines as an Adjuvant in the Treatment of COVID-19. Journal of Primary Care Specialties. 2022. doi:10.4103/jopcs.jopcs_13_22

BibTeX
@article{Javed2022,
  author = {Javed, Danish and Dixit, Ashish Kumar and Mukherjee, Sukhes and Anwar, Sana and Giri, Nibha},
  title = {Ayurveda, Unani, Siddha, and Homoeopathy Medicines as an Adjuvant in the Treatment of COVID-19},
  journal = {Journal of Primary Care Specialties},
  year = {2022},
  doi = {10.4103/jopcs.jopcs_13_22}
}
Kostenlos starten →